Product Information

Registration Status: Active

AGGRASTAT CONCENTRATE FOR INFUSION 0.25mg/ML is approved to be sold in Singapore with effective from 1999-05-17. It is marketed by DCH AURIGA SINGAPORE, with the registration number of SIN10931P.

This product contains Tirofiban 0.281mg/mL in the form of INJECTION. It is approved for INTRAVENOUS use.

This product is manufactured by Patheon Manufacturing Services LLC in UNITED STATES.

It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.



Tirofiban prevents the blood from clotting during episodes of chest pain or a heart attack, or while the patient is undergoing a procedure to treat a blocked coronary artery. It is a non-peptide reversible antagonist of the platelet glycoprotein (GP) IIb/IIIa receptor, and inhibits platelet aggregation.


For treatment, in combination with heparin, of acute coronary syndrome, including patients who are to be managed medically and those undergoing PTCA or atherectomy.

Mechanism of Action

Tirofiban is a reversible antagonist of fibrinogen binding to the GP IIb/IIIa receptor, the major platelet surface receptor involved in platelet aggregation. Platelet aggregation inhibition is reversible following cessation of the infusion of tirofiban.


* 213 - 314 mL/min [Healthy subjects] * 152 - 267 mL/min [patients with coronary artery disease]

Active Ingredient/Synonyms

(2S)-2-(Butylsulfonylamino)-3-[4-(4-piperidin-4-ylbutoxy)phenyl]propanoic acid | N-(Butylsulfonyl)-O-(4-(4-piperidyl)butyl)-L-tyrosine | Tirofiban | Tirofibanum | Tirofiban |

Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.


  1. Health Science Authority of Singapore - Reclassified POM
  2. Drugbank